Big Flats, NY – (August, 2013) – X-GEN Pharmaceuticals, Inc. announces FDA approval to begin marketing and distributing Tranexamic Acid Injection. Tranexamic Acid is the generic product AP rated to Cyklokapron® and works by blocking the breakdown of blood clots in hemophiliacs. Tranexamic Acid reduces or prevents hemorrhage and can also minimize the potential need for replacement therapy during and following tooth extraction.
The addition of Tranexemic Acid Injection to X-GEN’s current product line demonstrates the company’s strength and continued commitment toward improving healthcare through high quality, low cost generic treatment options. X-GEN’s expansion beyond its core product offerings creates exciting opportunities for the company to build upon its successful history and key industry relationships. Rob Liles, Corporate Vice President, stated that “We are excited to expand our product line and are confident this cost effective treatment option from X-GEN further illustrates our commitment to meeting the needs of the healthcare community.
X-GEN Pharmaceuticals, Inc. is focused on the development, manufacture and delivery of specialty pharmaceutical products which serve the healthcare community as effective, generic treatment choices. X-GEN’s expanding product line offers a broad range of dosage forms including injectables, anti-infective solutions, oral solids, powders for prescription compounding and inhalants. For further information about X-GEN Pharmaceuticals call (866) 390-4411, or visit the web-site at www.x-gen.us.
For further information contact:
X-GEN Pharmaceuticals, Inc.